ClinicalTrials.gg
Enrolling by invitationNCT05659147Updated Mar 18, 2026

Imaging Biomarkers of Pancreatic Function and Disease

A Phase 4 interventional study of Research MRI without administration of intravenous secretin and Research MRI with administration of intravenous secretin in Pancreatitis and Diabetes Mellitus, sponsored by Children's Hospital Medical Center, Cincinnati. Enrolling by invitation at 1 site in United States. Open to participants aged 5 Years to 21 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 4, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
195
Allocation
Non-randomized
Ages
5 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 139 studies in Pancreatitis with a site in United States — 44 open to participants now, 49 under way, 2 of them phase 3. Pancreatitis · United States.

Planned enrollment
18th of 97
195 · median 60
Started
2023
with 9 others
Phase 4
11 of 139
5 open now
Primary completion
2026-12
later than 11 of 48 live
Registered
110th of 139
by date

Among the 139 studies in Pancreatitis with a site in United States, this one is the 18th largest by planned enrollment of the 97 interventional ones that give a count, is one of 10 that started in 2023, is one of 11 in phase 4, reaches primary completion later than 11 of the 48 other live ones, and was the 110th registered.

Pancreatitis

558 studies on the registry are indexed under Pancreatitis; 165 are open to participants now.

Browse Pancreatitis studies →

Open to participants now

44 of the 139 studies in Pancreatitis with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Pancreatitis studies recruiting now, 62 (55%) set no upper age limit and 27 (24%) stop at 75 or younger; 14 take children under 18; 12 take healthy volunteers.

This study: 5 Years to 21 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Pancreatitis with a site in United States, or all of them as a file.
02

Study summary

This study seeks to understand the performance of MRI to characterize pancreatitis and predict chronic complications (endocrine and exocrine) of pancreatitis. Through multiple aims, the investigators will benchmark MRI against relevant reference standards (e.g. endoscopic pancreatic function tests, laboratory data). The investigators will also characterize repeatability of the imaging findings and will work to develop methods to simplify and automate analysis of the MRI images.

Research interventions depend on the Aim(s) participants enroll in but include: endoscopic pancreatic function testing (added on to clinically indicated upper GI endoscopy), blood tests, stool tests, gene sequencing, and survey completion. All participants will undergo research MRI examinations, a subset of which will include administration of intravenous secretin.

Read the detailed description

Pancreatitis can be acute [AP], acute recurrent [ARP] (defined as two discrete attacks with interval resolution), or chronic [CP]. Adult studies show that up to 40% of patients develop abnormal glucose metabolism after a single attack of AP, with a 2.5x increased risk of diabetes. CP is defined, in part, by the presence of established endocrine (diabetes) or exocrine pancreatic insufficiency [EPI]. Currently, it is not possible to non-invasively diagnose or predict development of pancreatitis-related endocrine or exocrine insufficiency.

The investigator's data has shown that CFTR gene variants play a significant role in progression to diabetes post first attack AP. Existing literature suggests that imaging findings such as decreased pancreas volume are associated with diabetes, but this has not been systematically studied in children.

EPI, defined as insufficient secretion of digestive enzymes and fluid by the pancreas, can have significant effects in childhood including malnutrition, osteoporosis, and growth failure. If diagnosed early, EPI can be treated with pancreatic enzyme replacement, improving nutrition and stabilizing growth. Unfortunately, diagnosing EPI early and accurately is a challenge in children and it is currently not possible to predict progression to CP or development of EPI.

Magnetic resonance imaging (MRI) is a powerful, non-invasive technique, capable of characterizing pancreatic disease. Quantitative non-contrast MRI techniques are attractive as potential markers of pancreatic disease but they have not been validated for diagnosis or prediction of diabetes or EPI in children and they have not been explored for staging of pediatric pancreatitis.

The overall goals of this study are to:

  1. Define associations between non-invasive, quantitative MRI measures and established measures of pancreas health and function including diabetes and EPI in children
  2. Identify clinical, genetic and imaging-related factors that predict progression to diabetes in children with pancreatitis.
03

Conditions studied

  • Pancreatitis
  • Diabetes Mellitus

Keywords

  • MRI
04

Who can participate

Ages eligible
5 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Aim 1-

Patient Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Scheduled for clinically-indicated gastrointestinal endoscopy
  • Clinical diagnosis or suspicion of exocrine pancreatic insufficiency

Exclusion Criteria:

  • Complete fatty replacement of pancreas on prior imaging
  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Control Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Scheduled for clinically-indicated gastrointestinal endoscopy

Exclusion Criteria:

  • Sweat chloride >60 mmol/L
  • Clinical diagnosis of gastrointestinal pathology
  • Clinical diagnosis or history of pancreatic disease
  • Complete fatty replacement of pancreas on prior imaging
  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Aim 2-

Acute Pancreatitis Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinically documented episode of acute pancreatitis

Exclusion Criteria:

  • More than one episode of acute pancreatitis
  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Pregnancy

Acute Recurrent Pancreatitis Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinical diagnosis of acute recurrent pancreatitis

Exclusion Criteria:

  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Pregnancy

Pancreatitis-Related Diabetes Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinical diagnosis of pancreatitis-related diabetes

Exclusion Criteria:

  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Pregnancy

Aim 3-

Control Group:

Inclusion Criteria:

  • Age 5 to \<21 years

Exclusion Criteria:

  • Sweat chloride >60 mmol/L
  • Clinical diagnosis of gastrointestinal pathology
  • Clinical diagnosis or history of pancreatic disease, including acute pancreatitis
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Acute Pancreatitis Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinically documented episode of acute pancreatitis

Exclusion Criteria:

  • More than one episode of acute pancreatitis
  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Acute Recurrent Pancreatitis Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinical diagnosis of acute recurrent pancreatitis with no evidence of CP or EPI

Exclusion Criteria:

  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Chronic Pancreatitis Group:

Inclusion Criteria:

  • Age 5 to \<21 years
  • Clinical diagnosis of chronic pancreatitis

Exclusion Criteria:

  • Current acute pancreatitis or acute pancreatitis less than 30 days prior to research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Aim 4-

Inclusion Criteria:

  • Age 5 to \<21 years
  • Completed research MRI under Aims 1 or 3 of this study

Exclusion Criteria:

  • Failed/unable to complete first research MRI under Aims 1 or 3
  • Episode of acute pancreatitis since first research MRI
  • Current acute pancreatitis
  • Any gastrointestinal surgery or pancreas intervention (e.g. ERCP) since first research MRI
  • Need for sedation for MRI
  • Contraindication to MRI (implanted metal hardware)
  • Allergy to secretin
  • Pregnancy

Aim 5-

Inclusion Criteria:

  • MRI performed at CCHMC

Exclusion Criteria:

  • Severe image artifact compromising image quality (judgement of study team)
  • Age >21 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Imaging markers of exocrine and endocrine insufficiency

    We will prospectively enroll 85 participants; 40 with known or suspected EPI and 45 controls (no known organic gastrointestinal pathology and no history of pancreatic disease) in this aim. Participants will be undergoing clinically-indicated endoscopy and will have endoscopic pancreatic function tests (ePFTs) collected for research during the clinically-indicated endoscopy examination. A research blood draw and a research stool collection will also be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin within 2 weeks of their clinical endoscopy but no sooner than 2 hours before or after endoscopy.

    Diagnostic Test: Research MRI with administration of intravenous secretin · Diagnostic Test: Blood Tests · Diagnostic Test: Stool Tests · Other: Survey Completion · Diagnostic Test: Endoscopic pancreatic function tests (ePFTs) · Drug: Secretin

  • Experimental
    Imaging markers of diabetes and prediction of progression to diabetes

    We will prospectively enroll 30 participants; 10 with a single episode of acute pancreatitis, 10 with acute recurrent pancreatitis, and 10 with pancreatitis-related diabetes in this aim. Participants will undergo a research MRI examination. Participants will also undergo a research blood draw for laboratory analysis and to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.

    Diagnostic Test: Research MRI without administration of intravenous secretin · Genetic: Genetic Sequencing · Diagnostic Test: Blood Tests · Other: Survey Completion

  • Experimental
    Imaging stratification of stages of pancreatitis

    We will prospectively enroll 60 participants; 15 healthy controls, 15 participants with a single episode of acute pancreatitis, 15 participants with acute recurrent pancreatitis, and 15 participants with chronic pancreatitis. A research blood draw and a research stool collection will be collected from all participants. Participants will undergo a research MRI examination with administration of intravenous secretin.

    Diagnostic Test: Research MRI with administration of intravenous secretin · Diagnostic Test: Blood Tests · Diagnostic Test: Stool Tests · Other: Survey Completion · Drug: Secretin

  • Experimental
    Imaging reproducibility

    We will prospectively enroll up to 20 participants enrolled in Aims 1 or 3 (up to 5 controls and 15 patients with pancreatic disease) to undergo repeat research MRI imaging between 24 hours and 14 days after their first research MRI. Participants will undergo a research MRI examination with administration of intravenous secretin, identical to the research MRI performed under Aims 1 or 3. MRI images will be quantitatively analyzed and agreement between the two MRI examinations (1st and repeat MRI) will be assessed.

    Diagnostic Test: Research MRI with administration of intravenous secretin · Drug: Secretin

  • No intervention
    Automated or semi-automated image analysis

    We will use images prospectively collected under Aims 1-3, as well as existing images that had been obtained for clinical care of children with pancreatitis at CCHMC to develop and optimize image processing pipelines for MRI images. Performance of these pipelines will be benchmarked against manual segmentation performed by multiple observers.

Interventions

  • Diagnostic testResearch MRI without administration of intravenous secretin

    Participants will undergo a research MRI examination. MRI images will be quantitatively analyzed and will be compared to / used to predict diabetes.

  • Diagnostic testResearch MRI with administration of intravenous secretin

    Participants will undergo a research MRI examination with intravenous administration of secretin. MRI images will be quantitatively analyzed and will be compared to / used to predict exocrine and endocrine pancreatic insufficiency based on the reference standards of ePFTs or fecal elastase and blood hemoglobin A1c (HbA1c) and fasting glucose, respectively.

  • GeneticGenetic Sequencing

    Blood will be drawn to enable gene sequencing for gene mutations associated with heritable pancreatitis. We will assess the association between identified gene variants and the presence of diabetes and will construct models based on identified variants to predict progression to diabetes.

  • Diagnostic testBlood Tests

    Research blood draw (for markers of pancreatic endocrine insufficiency)

  • Diagnostic testStool Tests

    Research stool collection (for fecal elastase as a marker of exocrine insufficiency)

  • OtherSurvey Completion

    Participants will be contacted to complete a survey and their charts will be reviewed annually after research MRI to identify any evidence of subsequent development of pancreatic endocrine insufficiency or progression of pancreatitis. Survey and chart review will occur within +/- 14 days of the anniversary date.

  • Diagnostic testEndoscopic pancreatic function tests (ePFTs)

    At least two duodenal fluid aspirates will be collected over 15 minutes following secretin administration. Aspirates will be immediately pH tested and will be submitted for analysis of bicarbonate, enzyme (trypsin, amylase, lipase, chymotrypsin) activity, and total protein.

  • Participants enrolled in Aim 1, Aim 3, and Aim 4 will receive intravenous secretin at a dose of 0.2 mcg/kg (maximum 16 mcg). Participants in Aim 1 will receive two doses (1 during endoscopy and 1 during MRI). Participants in Aim 3 will receive one dose during MRI. Participants in Aim 4 will receive two doses (1 during each MRI). Secretin for intravenous use is FDA-approved for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of exocrine pancreas dysfunction. Safety and effectiveness of secretin in pediatrics have not been established. However, secretin is routinely used in children at CCHMC at the same dose at which it will be administered for this study.

06

What researchers measure

Primary outcomes

  1. Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  2. Pancreas volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  3. Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas T1 signal (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  4. Pancreas T1 signal as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas T1 signal intensity (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  5. Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. exocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  6. Pancreas secreted fluid volume as a predictor of pancreas health and function (including endocrine and exocrine pancreatic insufficiency).

    2 x 2 table analyses of pancreas secreted fluid volume (categorized as normal vs. abnormal) vs. endocrine function (categorized as normal vs. abnormal)

    Time frame: 5 years

  7. Frequency of genetic mutations in patients progressing to diabetes vs. those not

    Frequency of genetic mutations in each study group will be compared using 2x2 tables to identify mutations associated with development of diabetes

    Time frame: 5 years

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2022
First posted
Dec 21, 2022
StartActual
Jan 18, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05659147
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Jan 18, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Andrew Trout, MD
principal investigator · Children's Hospital Medical Center, Cincinnati

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secretin

Start the discussion